帕金森病 (PD) 是一种慢性神经退行性疾病，其临床表现包括运动迟缓、运动功能减退、僵硬、静止性震颤和姿势不稳。最近，神经炎症参与PD的发病机制。非甾体类抗炎药治疗这些神经炎症的应用引起了人们的关注。为了探讨塞来昔布对接受常规治疗的PD患者的可能疗效。这项随机、前瞻性、对照研究纳入了60名符合PD纳入要求的门诊患者。 。将患者随机分为两组（n = 30）；对照组接受标准PD治疗，由左旋多巴/卡比多巴组成，塞来昔布组接受标准PD治疗加塞来昔布。神经科医生在治疗开始时和 6 个月后对每位患者进行了评估。对每位患者进行统一帕金森病评定量表 (UPDRS) 的评估。治疗前后，α-突触核蛋白（α-Syn）、肿瘤坏死因子α（TNF-α）、Toll样受体-4（TLR-4）、核因子红细胞2相关因子2（Nrf-2）和脑评估了衍生性神经营养因子（BDNF）。配对和非配对t检验分别用于评估组内和组间的统计学显着性。塞来昔布组通过非配对t检验显示测量参数水平显着且统计学降低，如下：TLR-4（p = 0.004）、TNF-与对照组相比，α（p = 0.042）和α-Syn（p = 0.004）除了BDNF（p = 0.0005）和Nrf-2（p = 0.004）显着增加外。此外，塞来昔布组的 UPDRS 显着降低 (p< 0.05)。塞来昔布可能是治疗 PD 患者的一种有前景的辅助疗法。NCT05962957.© 2024。作者获得 Springer Nature Switzerland AG 的独家许可。

The clinical presentations of Parkinson's disease (PD), a chronic neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor, and postural instability. Recently, neuroinflammation is involved in pathogenesis of PD. Application of nonsteroidal anti-inflammatory drugs captured attention to treat these neuroinflammation.To investigate the possible effectiveness of celecoxib in patients with PD treated with conventional treatment.Sixty outpatients who fulfilled the inclusion requirements for PD were enrolled in this randomized, prospective, and controlled study. The patients were allocated into two groups at random (n = 30); the control group received standard PD treatment, consisting of levodopa/carbidopa, and the celecoxib group received standard PD treatment plus celecoxib. A neurologist evaluated each patient at the beginning of the treatment and after 6 months. Assessment of Unified Parkinson's disease rating scale (UPDRS) for each patient. Before and after treatment, α -synuclein (α-Syn), tumor necrosis factor alpha (TNF-α), Toll like receptors-4 (TLR-4), nuclear factor erythroid 2-related factor 2 (Nrf-2) and brain-derived neurotropic factor (BDNF) were assessed. Paired and unpaired t tests were used to assess statistical significance within and between groups respectively.The celecoxib group exhibited a significant and statistical reduction in the level of measured parameters by unpaired t test as followed: TLR-4 (p = 0.004), TNF-α (p = 0.042), and α-Syn (p = 0.004) apart from a significant increase in BDNF (p = 0.0005) and Nrf-2 (p = 0.004), in comparison with the control group. Also, UPDRS was significantly decreased in celecoxib group (p < 0.05).Celecoxib could be a promising adjuvant therapy in managing patients with PD.NCT05962957.© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.